Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2020/07/13 18:01:45」(JST)

wiki en

Vonoprazan (trade name Takecab) is a first-in-class potassium-competitive acid blocker. It was approved in the Japanese market in February 2015.^[1]

Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.^[2]

References

^ Garnock-Jones KP (2015). "Vonoprazan: first global approval". Drugs. 75 (4): 439–43. doi:10.1007/s40265-015-0368-z. PMID 25744862.
^ Echizen H (2016). "The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations". Clin Pharmacokinet. 55 (4): 409–18. doi:10.1007/s40262-015-0326-7. PMID 26369775.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 抗潰瘍薬：作用機序、薬理作用、副作用antiulcer medications mechanism of action pharmacology and side effects [show details]
…ulcers has been similar to proton pump inhibitor therapy with a comparable safety profile . The PCAB vonoprazan has been approved for the prevention of nonsteroidal anti-inflammatory drug-induced ulcers and …
2. ヘリコバクターピロリ菌の治療レジメンtreatment regimens for helicobacter pylori [show details]
…antibiotic treatment regimens to eradicate H. pylori. Vonoprazan – Limited data from retrospective studies suggest that the use of vonoprazan, an oral potassium-competitive acid blocker (PCAB), rather…

English Journal

Japanese Journal

Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis

Takenouchi Nana,Hoshino Shintaro,Hoshikawa Yoshimasa,Tanabe Tomohide,Koeda Mai,Momma Eri,Ishikawa Yumiko,Kawami Noriyuki,Kaise Mitsuru,Iwakiri Katsuhiko
Esophagus : official journal of the Japan Esophageal Society 17(1), 87-91, 2020-01
NAID 40022141210

Effectiveness of including probiotics to Helicobacter pylori eradication therapies

Mukai Rieko,Handa Osamu,Suyama Yosuke,Majima Atsushi,Naito Yuji
Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｂｉｏｃｈｅｍｉｓｔｒｙ　ａｎｄ　Ｎｕｔｒｉｔｉｏｎ, 2020
… They were divided into three groups based on their treatment regime, being either proton pump inhibitors, amoxicillin, or clarithromycin (PPI group), vonoprazan, amoxicillin, or clarithromycin (VPZ group), and proton pump inhibitors, amoxicillin, or clarithromycin/probiotics (Miya-BM®) (PPI + MBM group). …
NAID 130007852177

ボノプラザン使用ピロリ菌除菌により低血糖を呈した経口血糖降下薬使用中2型糖尿病患者の1例

湧田健一郎,前川陽子,渡辺蔵人,屋良朝博,城間勲
糖尿病 63(5), 339-343, 2020
過去の報告においてグリベンクラミド，グリブリド，グリピジドなどのSulfonylurea（SU）薬とピロリ菌除菌薬の併用で低血糖の発現の報告は散見されるが，現在日本において使用頻度の高いグリメピリドとピロリ菌除菌薬との併用で低血糖を認めた症例報告はなく，また，新規の制酸薬であるボノプラザンを使用したピロリ菌除菌で低血糖を認めた症例は報告がない．今回我々はグリメピリド使用中の2型糖 …
NAID 130007849545

「ボノプラザン」

Vonoprazan
Clinical data
Trade names	Takecab
ATC code	A02BC08 (WHO) ;
Pharmacokinetic data
Bioavailability	Unknown
Protein binding	80%
Metabolism	Hepatic, by cytochrome P450 (3A4, 2B6, 2C19, 2D6)
Elimination half-life	7.7 h
Duration of action	> 24 h
Excretion	Renal
Identifiers
	IUPAC name 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine;
CAS Number	881681-00-1 1260141-27-2 (fumarate);
DrugBank	DB11739;
ChemSpider	13112797;
UNII	1R5L3J156G;
KEGG	D10466;
Chemical and physical data
Formula	C17H16FN3O2S
Molar mass	345.39 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc1ccccc1-c2cc(CNC)cn2S(=O)(=O)c3cccnc3;
	InChI InChI=InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3; Key:BFDBKMOZYNOTPK-UHFFFAOYSA-N;

　　[★]

英: vonoprazan
商: タケキャブ
関: キャブピリン配合(アスピリン+ボノプラザン)

[1] Garnock-Jones KP (2015). "Vonoprazan: first global approval". Drugs. 75 (4): 439–43. doi:10.1007/s40265-015-0368-z. PMID 25744862.

[2] Echizen H (2016). "The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations". Clin Pharmacokinet. 55 (4): 409–18. doi:10.1007/s40262-015-0326-7. PMID 26369775.

v t e Drugs for peptic ulcer and GERD/GORD (A02B)
H₂ antagonists ("-tidine")	Cimetidine Famotidine Lafutidine Lavoltidine (loxtidine) Niperotidine Nizatidine Ranitidine^# Roxatidine
Prostaglandins (E)/analogues ("-prost-")	Misoprostol Enprostil
Proton-pump inhibitors ("-prazole")	Azeloprazole Dexlansoprazole Esomeprazole Ilaprazole Lansoprazole Omeprazole^# Pantoprazole Picoprazole Rabeprazole Tenatoprazole Timoprazole
Potassium-competitive acid blockers ("-prazan")	Linaprazan Revaprazan Soraprazan Vonoprazan
Others	Aceglutamide aluminum Acetoxolone Alginic acid Arbaclofen placarbil Bismuth subcitrate Carbenoxolone Cetraxate Gefarnate Lesogaberan Pirenzepine Proglumide Rebamipide Sucralfate Sulglicotide Telenzepine Teprenone Troxipide Zinc L-carnosine Zolimidine
Combinations	Bismuth subcitrate/metronidazole/tetracycline
See also: Helicobacter pylori* eradication protocols*
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

匿名

検索

案内

案内

vonoprazan